Biocartis Group NV (EBR:BCART)
Belgium
· Delayed Price · Currency is EUR 0.2900
0.00 (0.00%)
At close: Aug 15, 2025, 5:30 PM CET
Biocartis Group NV Revenue
In the year 2023, Biocartis Group NV had annual revenue of 47.69M EUR, down -17.74%. Biocartis Group NV had revenue of 29.62M in the half year ending June 30, 2023, with 28.45% growth.
Revenue
47.69M
Revenue Growth
-18.19%
P/S Ratio
0.57
Revenue / Employee
95.38K
Employees
500
Market Cap
27.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 47.69M | -10.29M | -17.74% |
| Dec 31, 2022 | 57.98M | 3.08M | 5.61% |
| Dec 31, 2021 | 54.90M | -661.00K | -1.19% |
| Dec 31, 2020 | 55.56M | 17.83M | 47.25% |
| Dec 31, 2019 | 37.73M | 9.08M | 31.70% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UCB SA | 6.85B |
| argenx SE | 2.66B |
| Financière de Tubize | 13.26K |
| Fagron NV | 918.75M |
| Ion Beam Applications | 498.16M |
| Nyxoah | 4.36M |
| Onward Medical | 1.74M |
| Hyloris Pharmaceuticals | 9.76M |